Novick, D., Haro, JM, Suarez, D., Perez, V., Dittmann, RW, Haddad, PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res
2010; 176: 109–13.
Barnes, TRE, Curson, DA. Long term depot antipsychotics: a risk–benefit assessment. Drug Saf
1994; 10: 464–79.
Barnes, TRE, Shingleton-Smith, A., Paton, C.
Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry
2009; 195 (suppl): s37–42.
David, AS, Adams, C.
Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) meta-review; (2) patient and nurse attitudes. Health Technol Assess
2001; 5: 1–79.
Patel, MX, David, AS. Why aren't depot antipsychotics prescribed more often and what can be done about it?
Adv Psychiatr Treat
2005; 11: 203–11.
Patel, MX, Haddad, PM, Chaudhry, IB, McLoughlin, S., Husain, N., David, AS. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol
2010; 24: 1473–82.
National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update), CG82.
Barnes, TRE. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol
2011; 25: 567–620.
Adams, CE, Fenton, MKP, Quraishi, S., David, AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry
2001; 179: 290–9.
Haddad, PM, Taylor, M., Niaz, OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry
2009; 195: s20–8.
Leucht, C., Heres, S., Kane, JM, Kissling, W., Davis, JM, Leucht, S.
Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res
2011; 127: 83–92.
Rosenheck, RA, Krystal, JH, Lew, R., Barnett, PG, Fiore, L., Valley, D., et al Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med
2011; 364: 842–51.
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., et al Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet
2012; 379: 2063–71.
Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., et al Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull
Zhu, B., Ascher-Svanum, H., Shi, L., Faries, D., Montgomery, W., Marder, SR. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv
2008; 59: 315–7.
Tiihonen, J., Haukka, J., Taylor, M., Haddad, PM, Patel, MX, Korhonen, P.
A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry
2011; 168: 603–9.
Grimaldi-Bensouda, L., Rouillon, F., Astruc, B., Rossignol, M., Benichou, J., Falissard, B., et al Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res
2012; 134: 187–94.
Bitter, I., Katona, L., Zámbori, J., Takács, P., Fehér, L., Diels, J., et al Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary. Eur Neuropsychopharmacol
Lambert, T., Olivares, JM, Peuskens, J., Desouza, C., Kozma, CM, Otten, P., et al Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry
2011; 10: 10.
Peng, X., Ascher-Svanum, H., Faries, D., Conley, RR, Schuh, KJ. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res
2011; 3: 9–14.
Bowen, J., Barnes, TRE. The clinical characteristics of schizophrenic patients consenting and not consenting to a placebo-controlled trial. Hum Psychopharmacol
1994; 9: 423–33.
Jones, PB, Barnes, TRE, Davies, L., Dunn, G., Lloyd, H., Hayhurst, KP, et al Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry
2006; 63: 1079–87.
Lewis, SW, Barnes, TRE, Davies, L., Murray, RM, Dunn, G., Hayhurst, KP, et al Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull
2006; 32: 715–23.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV).
Heinrichs, DW, Hanlon, TE, Carpenter, WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull
1984; 10: 388–98.
Kay, SR, Fiszbein, A., Opler, LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull
1987; 13: 261–76.
Addington, D., Addington, J., Schissel, B.
A depression rating scale for schizophrenics. Schizophr Res
1990; 3: 247–51.
Hogan, TP, Awad, AG, Eastwood, R.
A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med
1983; 13: 177–83.
Hayward, P., Chan, N., Kemp, R., Youle, S., David, A.
Medication self-management: a preliminary report on an intervention to improve medication compliance. J Ment Health
1995; 4: 511–7.
Yusufi, B., Mukherjee, S., Flanagan, R., Paton, C., Dunn, G., Page, E., et al Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol
2007; 22: 238–43.
Ohlsen, RI, Williamson, R., Yusufi, B., Mullan, J., Irving, D., Mukherjee, S., et al Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine. J Psychopharmacol
2008; 22: 323–9.
Simpson, G., Angus, J.
A rating scale for extrapyramidal side effects. Acta Psychiatr Scand
1970; 45: 11–9.
Barnes, TR. A rating scale for drug-induced akathisia. Br J Psychiatry
1989; 154: 672–6.
ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM). National Institute for Mental Health, 1976.